Study of LYL314 in Aggressive Large B-Cell Lymphoma

Study Number

4566925

Phase

I/II

Age Group

Adult

Principal Investigator

Francisco Hernandez-Ilizaliturri

Purpose

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Check your eligibility for this trial

Check now

Full Title

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of LYL314, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants with Aggressive B-Cell Non-Hodgkin Lymphoma (LYL314-101)

ClinicalTrials.Gov ID

NCT05826535

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.